By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche has extended its $5.7 billion hostile takeover bid for Illumina for another month at the same price, the company said today.

Roche's offer for Illumina, at $44.50 per share, was set to expire on March 23. The company has now extended it to April 20 at 6 pm EDT, keeping all terms and conditions the same. This is the second time Roche has prolonged the offer, which originally expired Feb. 24.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.